St. Rita’s introduces new heart stent
LIMA — Since the 1980s, cardiologists have been using tiny wired mesh stents to help treat narrow or blocked arteries and restore blood flow to the heart.
The cardiology team at St. Rita’s Medical Center now have access to a new type of stent — Abbott’s Absorb bioresorbable stent. This stent was approved by the U.S. Food and Drug Administration in July, and is the only fully dissolving heart stent.
Since the stent is naturally dissolving, like stitches, the treated artery can pulse and flex naturally, a press release stated. This also means that the naturally absorbing stent may reduce the potential of future blockages that can occur with metal stents.
Initiative aims to curb cancer diagnoses
LIMA — The Ohio Colorectal Cancer Prevention Initiative is a statewide effort to curb the amount of cancer diagnoses in the state.
It is made up of a network of 50 hospitals across the state, including St. Rita’s Medical Center. The initiative uses a simple blood test to identify individuals who are most at risk. Like the BRCA for colon cancer, a gene deformity known as Lynch syndrome causes a nearly 100-percent chance of developing cancer.
The free screening effort targets people who have close relatives diagnosed with colorectal cancer, since Lynch syndrome is hereditary. This group is most at risk of having the genetic deformity and developing cancer as a result. Through proactive measures, cancers can be caught and treated when remission is most possible.
Naloxone price to freeze for one year
COLUMBUS — Ohio Attorney General Mike DeWine has announced that Adapt Pharma will freeze the Public Interest Price for its naloxone nasal spray for Ohio over the next year.
Ohio is currently the only state in the country that has secured a price freeze with the company.
When given to a person overdosing on opioids such as heroin, fentanyl, carfentanil, or a prescription opioid, naloxone can limit or stop the overdose by reversing the effects of the opioid on the brain.
The Public Interest Price will apply for one year to qualified purchasers who purchase two, 4-mg doses of the nasal spray for $75, when obtained directly from Adapt Pharma in quantities greater than 48 units. That cost is a 40-percent discount from Adapt Pharma’s Wholesale Acquisition Cost of $125.
Reach John Bush at 567-242-0456 or on Twitter @bush_lima